Skip to main content
. Author manuscript; available in PMC: 2017 May 17.
Published in final edited form as: Cancer. 2010 Nov 15;116(22):5272–5278. doi: 10.1002/cncr.25516

Figure 1.

Figure 1

Overall survival is shown for patients treated with the combination of daunorubicin, cytarabine, thioguanine, etoposide, and prednisone (DCTER regimen) versus those treated with idarubicin (IDA) and cytarabine (AC).